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Nuclear receptor coactivatorNF-κB regulates the expression of Cyclin D1 (CD1), while RAC3 is an NF-κB coactivator that enhances its tran-
scriptional activity. In this work, we investigated the regulatory role of CD1 on NF-κB activity. We found that
CD1 inhibits NF-κB transcriptional activity through a corepressor function that can be reverted by over-
expressing RAC3. In both, tumoral and non-tumoral cells, the expression pattern of RAC3 and CD1 is regu-
lated by the cell cycle, showing a gap between themaximal expression levels of each protein. The individual
increase, by transfection, of either CD1 or RAC3 enhances cell proliferation. However the simultaneous and
constitutive over-expression of both proteins has an inhibitory effect. Our results suggest that the relative
amounts of CD1 and RAC3, and the timing of expression of these oncogenes could tilt the balance of
tumor cell proliferation in response to external signals.
© 2012 Published by Elsevier B.V.1. Introduction
NF-κB is a transcription factor formed by protein dimmers con-
taining the Rel dimerization domain, where Rel-A (p65)/p50 hetero-
complex is the best characterized and plays a pivotal role in the reg-
ulation of diverse biological processes, including immune response,
development, cell growth and survival [1,2]. NF-κB can be rapidly
and transiently activated by a large variety of stimuli, such as DNA
damage, cytokines, microbial components and mitogens [3], and in-
duces a variety of genes involved in cell proliferation and survival,
including Cyclin D1 (CD1) [4,5]. Gene transactivation, induced by
NF-κB, is regulated by a dynamic balance between the activity of
coactivators and corepressors [6,7]. The deregulated function of
NF-κB contributes to the development of a variety of human diseases,
particularly immune-related diseases and cancers [8–10].
In human breast cancer, NF-κB stimulates tumor cell prolifera-
tion and blocks programmed cell death [11,12]. Particularly, the
transcriptionally active form of this factor was detected in estrogennt kinase; ER, Estrogen recep-
MA, 12-O-tetraecanoylphorbol-
ic acid coactivator
olecular y Apoptosis, Instituto
ICET), Universidad de Buenos
os Aires, Argentina. Fax: +54
ostas).
sevier B.V.receptor (ER)-negative tumors and has been linked to tumor devel-
opment [13]. Moreover, the activation of NF-κB is also required for
estrogen-induced proliferation in ER-positive tumor cells [14]. Such
effects of estrogens are mediated by a complex that contains the acti-
vated ER, the nuclear receptor coactivator RAC3 and a member of the
NF-κB family that induces CD1 expression through the binding to a con-
served sequence that contains κB elements in the promoter of the gene
[4,5].
RAC3 is a member of the Steroid Receptor Coactivator (SRC) fam-
ily that enhances the transcriptional activity of several nuclear re-
ceptors and NF-κB [6,15–17]. The molecular mechanism by which
coactivators induce chromatin remodeling and transcriptional acti-
vation involves a histone acetyltransferase (HAT) activity, present
in the C-terminal domain of SRC-1 and RAC3 [18,19], and the recruit-
ment of other general coactivators such as CBP/p300, p/CAF, CARM-1
and PRMT1 [20,21].
On the other hand, CD1 is considered an oncogene with an impor-
tant tumorigenic role in breast cancer and other human tumors [22].
Emerging evidence suggests that CD1 may act through novel path-
ways that do not involve its widely accepted function on the cell
cycle. Instead, it may also exhibit such novel activities independently
of its function as Cyclin-dependent kinase (Cdk) regulatory subunit
[23–25]. It has been suggested that CD1 may activate ER-α-mediated
transcription through a direct interaction with the ligand-binding
domain of the receptor, and the recruitment of the SRC coactivators
[26]. A similar mechanism, but with opposite effect, has been reported
for the Androgen Receptor (AR), where CD1 has an inhibitory role
[27]. In this case, the mechanism appears to partially depend on both
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tivators, such as p/CAF [28]. In agreement with these observations,
over-expression of CD1 inhibits the activation of the Thyroid Recep-
tor (TR) in both ligand-dependent and independent manners, by
recruiting HDAC3 [29].
We and others have previously demonstrated that NF-κB activity
is regulated by coactivators that usually bind to nuclear receptors
[6,15–17]. On the other hand, although CD1 is a target gene for
NF-κB, it has the ability of recruiting coactivators and corepressors.
These evidences suggest the existence of a complex regulatory
network involved in the control of the cell cycle-dependent gene
expression.
Thus, in this work we investigated the role of CD1 as a regulator
of NF-κB activity. We found that CD1 physically interacts with NF-κB
and inhibits its transactivation in an HDAC-dependent way. Our
results support the existence of an unexpected antagonistic rela-
tionship between CD1 and RAC3, usually over-expressed in tumors.
These results have important implications for the understanding of
the regulatory networks that affect the progression of cancer.Fig. 1. Cyclin D1 inhibits the transcriptional activity of NF-κB.HEK293 cells were transfected
gal. A. The diagram bars correspond to the average±SD of relative light units normalized w
PMA (10 ng/ml). B. The whole extract of cells from T47D and HEK293, wild type or transfe
antibody. Relative densitometric units (RDU) correspond to the average of densitometr
independent experiments. Only when X-ray plaques were over-exposed levels of CD1 w
blot of CD1 that shows the effect of CD1 siRNA in HEK293 cells after 18 h of transfection
β-galactosidase values where cells were stimulated by 18 h with PMA in the presence of CD1 s
the average±SD, normalized with the corresponding β-galactosidase values. F. Western blot o
vector and stimulated with PMA (10 ng/ml) by 18 h. G. Levels of Vimentin mRNA determined
mRNA of GAPDH.*, ** signiﬁcantly lower than values without CD1 over-expression, pb0.001.
pb0.001.b, signiﬁcantly different with respect to the values with CD1 without CD1 siRNA plu
CD1 siRNA, pb0.001.d, signiﬁcantly different with respect to the basal values with CD1 withou2. Materials and methods
2.1. Cell culture and reagents
The human breast tumor T47D cells were grown in Dulbecco's
modiﬁed Eagle's F12 medium (DMEM-F12) and the human embryonic
kidney HEK293 cells were maintained in DMEM (Gibco Laboratories,
Grand Island, NY, USA) supplemented with 10% fetal bovine serum
(FBS) (Invitrogen), penicillin (100 U/ml) and streptomycin (100 mg/
ml). Cells were maintained at 37 °C in a humidiﬁed atmosphere with
5% CO2. Unless stated otherwise, all reagents were obtained from Sigma
Chemical Co. or Santa Cruz Biotechnology, USA. For all the experiments
the relative densitometric units (RDU) were determined from the origi-
nal gel or picture using the NIH-Image J software.
2.2. Expression vectors and reporter plasmids
The reporter plasmid containing the consensus sequence for binding
of NF-κB (κB-Luc) and plasmid containing the CD1 promoter upstreamwith different masses of CD1 plasmid, along with reporter plasmids κB-Luc and RSV-β
ith the corresponding β-galactosidase values, where cells were stimulated for 6 h with
cted with increasing mass of CD1, was analyzed by Western blot with a CD1-speciﬁc
ic units, of CD1 expression with respect to the tubulin expression, obtained in ﬁve
ere detected in HEK293 wild type and transfected with empty vector. C. Western
. D. The relative light units are the average±SD normalized with the corresponding
iRNA or the empty vector. E. Cells were stimulated for 6 h with TNF-α (20 ng/ml). RLU are
f Vimentin and CD1 in HEK293 cells, transfectedwith different amounts of CD1 expression
by RT-PCR at similar experimental conditions as F. The values were normalized with the
a, signiﬁcantly different with respect to the values without CD1 or CD1 siRNA plus PMA,
s PMA, pb0.001c, signiﬁcantly different with respect to the basal values without CD1 or
t CD1 siRNA, pb0.01.Analyzed by Tukey's Test.
Fig. 1 (continued).
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expression vector for pCMX-RAC3 was a gift from Dr. R. Evans, The
Salk Institute, San Diego, USA. Dr. Eduardo Canepa, Universidad de
Buenos Aires, Argentina kindly provided bacterial expression vectors
encoding Cyclin D1. The full-length Cyclin D1 gene was cloned into
pcDNA6/V5-His ABC (Invitrogen) at the Bam H1 and Eco R1 sites.
The pSilencer-CD1 small interfering RNA (siRNA) plasmid was pre-
pared using Ambion system following the manufacturer's protocol
according to the previously reported sequence [30] and a control
scrambled siRNA was obtained from Dharmacon Research, Inc. The
ssIκB expression vector carrying the mutated IκB at Ser32 and Ser36
to prevent phosphorylation and proteolysis was generously provided
by Dr. G. Cadwell and Dr. M. Karin (University of California, La Jolla,
CA, USA).
2.3. Immunoprecipitation and Western blot analysis
Co-immunoprecipitation and Western blot were performed as
previously described [14]. Brieﬂy, for immunoprecipitation assays,
after 45 min of incubation with 10 ng/ml of phorbol ester 12-0-tetraecanoylphorbol-13-acetate (PMA), T47D or HEK293 cells were
scraped and treated with RIPA buffer containing aprotinin, pepstatin
A, phenymethylsulfoyl ﬂuoride (PMSF) and 1 mM dithiothreitol
(DTT). Protein extracts were incubated overnight at 4 °C with anti-
CD1, anti-Rel-A or anti-Cdk4 antibodies (Santa Cruz Biotechnology,
USA) and immunoprecipitated for 2 h at 4 °C with GammaBind
Sepharose-protein G. After six washes with RIPA buffer, Sepharose-
bound immunocomplexes were solubilized in SDS-PAGE sample
buffer, separated on 10% SDS-PAGE, and electro-transferred to a PVDF
membrane.
For these experiments HEK293 cells were synchronized by serum
starvation for 16 h and growth was stimulated by supplementation of
medium with 10% serum. Cell extracts were prepared 18 h later.
NF-κB nuclear translocation was determined in nuclear cell ex-
tracts from HEK293 cells transfected with different amounts of CD1
expression vector. Cell lysates of these cells were separated on 10%
SDS-PAGE and electro-transferred to a PVDF membrane.
For experiments where CD1 or RAC3 expression was determined,
HEK293 or T47D cells grown to 60% of conﬂuence were serum-
starved for 16 h. Thereafter, medium containing 10% FBS was added
in order to promote cells to enter in cell cycle. At speciﬁc time points
after medium change, cells were harvested, and treated with lysis
buffer plus protease inhibitors as described above. Samples were
separated on 12% or 6% SDS-PAGE and electro-transferred to PVDF
membranes.
Membranes were blocked for nonspeciﬁc binding with 5% bovine
serum albumin (IgG-free) and 0.05% Tween-20 and incubated for
2 h at room temperature in PBS with 0.5 μg/ml of anti-Rel-A, anti-
CD1, anti-Cdk4, anti-Histone 3, anti-Vimentin, anti-Tubulin or anti-
RAC3 antibodies. Subsequently, washed membranes were incubated
for 1 h with HRP-conjugated secondary antibody (VECTOR), devel-
oped by chemioluminescence (Santa Cruz Biotechnology, USA).
2.4. Luciferase assays
HEK293 cells were plated in 24-well plates 24 h prior to transfection
at a density of 250,000 cells/well. Cells were transiently transfected
with a total of 0.2 μg of DNA (including pcDNA6-CD1 or pCMX-RAC3
or pSilencer-CD1-siRNA plus 20 ng of κB-Luc plasmid or 20 ng of
PromCD1-Luc and 5 ng RSV-β Gal) using the calcium phosphate pre-
cipitation method. The medium was replaced after 5 h and cells
were stimulated with 10 ng/ml of PMA or 20 ng/ml of human TNF-
α 2 h later.
The assays for luciferase and β-galactosidase activity were per-
formed after 6 h of treatment using the appropriate substrates fol-
lowing the manufacturer's protocols (Promega Corp.). To achieve
transfections with a constant amount of DNA, appropriate amounts
of the parental empty expression vector (pcDNA6/V5-His ABC or
pCMX) were added to each well. In some experiments, cells were
pre-incubated with deacetylases inhibitor Trichostatin A (TSA) for
30 min before stimulation with PMA.
For assays of Cyclin D1-promotor activity, HEK293 cells were
transfected with the reporter plasmid PromCD1-Luc plus pcDNA6-
CD1, the ssIκB expression vector or the empty vector together with
RSV-β-Gal. The assays for luciferase and β-galactosidase activity were
performed after 24 h of treatment with PMA (10 ng/ml) using the
appropriate substrates following the manufacturer's protocols (Pro-
mega Corp.).
2.5. Electrophoretic mobility shift assay (EMSA)
HEK293 cells transiently transfected with expression vector for
CD1 24 h, were then stimulated with 10 ng/ml of PMA for 60 or
180 min and EMSA was performed as previously described [14].
Brieﬂy, for each assay, 5 μg of nuclear extracts were incubated with
1 ng of κB probe, containing the sequence 5′-AGTTGAGGGGACTTTCC
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competition assays, 5–20 fold excess of the unlabeled κB oligonucle-
otide was utilized. Complexes were separated in non-denaturing 5%
PAGE. Gels were dried under vacuum and autoradiographed at
−70 °C.
2.6. Chromatin immunoprecipitation (ChIP)
After incubation for different time periods with 20 ng/ml of TNF-
α, T47D or HEK293 cells were ﬁxed with 1% of formaldehyde for
10 min and the ChIP was performed as described previously [14].
Immunoprecipitation was performed using 25 μg of DNA in RIPA
buffer with anti-Rel-A, anti-CD1, anti-RAC3 or anti-HDAC1 antibodies
for 18 h at 4 °C in an orbital rocker. Immunoprecipitates were then
incubated with GammaBind Sepharose-protein G (GE) for 2 h at
4 °C in an orbital rocker. After three washes, DNA was eluted fromFig. 2. Effect of cyclin D1 on NF-κB nuclear localization and DNA-binding activity.A. HEK293
After 24 h cells were stimulated, during 1 or 3 h, with PMA (10 ng/ml). Nuclear extracts we
NF-κB binding site. B. The speciﬁc binding was determined by competition with unlabeled κ
antibody against Rel-A, CD1 or Histone 3.the pellets, and proteins were digested with Proteinase K. Samples
were heated with shaking at 65 °C for 4 h to reverse crosslinking.
The extract containing DNA was precipitated with ethanol 70%
and sodium acetate 0.3 M. Samples were resuspended in buffer TE
and PCR was performed using the primers 5′-TCCATTCAGAGGTGTG
TTTCTC-3′ and 5′-GGATTTCAGCTTAGCATGCG-3′ that correspond to the
distal −749 and −858 κB elements of the CD1 promoter [4,5,14]. The
IκB-α primers were designed to cover the NF-κB binding site (−352/
+1) in the human IκB-α gene promoter [31] forward: 5′-GGATCTCAG
CAGCCGACGAC-3′ and reverse: 5′-CCCTA TAAACGCTGGCTG-3′ and per-
forming 35 cycles.
2.7. Proliferation assays
HEK293 cells transiently transfected with the expression vectors
for CD1, RAC3, both simultaneously or the empty vectors, werecells were transfected with 0.1 μg of a CD1 expression vector, or with an empty vector.
re prepared and analyzed by EMSA using double-strain oligonucleotides containing the
B oligonucleotide. C. Nuclear extracts were analyzed by Western blot and probed with
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100 μl of medium. After 24 h, mediumwas replaced with serum-free
medium and 16 h later, cells were released to the cell cycle by addi-
tion of medium containing 10% FBS. Cells were ﬁxed at speciﬁc time
points after medium change and the proliferation was determined
by staining with 0.5% crystal violet. Absorbance of surviving stained
cells was measured at 570 nm.2.8. Soft-agar colony formation assay
HEK293 cells were transfected as described above. Twenty-four
hours after transfection, cells were detached from the plates with
trypsin. Cells were resuspended as individuals in DMEM growth
medium with the full supplements described above mixed at a 2:1
ratio with agarose 0.7%. The mixture was then plated onto six-well
plates at 5×104 cells/well over a bottom layer of 0.5% agarose inFig. 3. Repression of NF-κB through CD1 involves deacetylases and is reversed by RAC3 ov
RSV-β Gal in the presence or absence of increasing amounts of CD1 expression vector. Cel
10 ng/ml for 6 h. B. Co-expression of increasing amounts of RAC3 expression vector, plu
average of triplicate±SD, and were normalized with the corresponding β-galactosidase
GAPDH.* pb0.001 with respect to the values without CD1 over-expression.**, ***, **** pb0.00
with respect to the values without RAC3 over-expression.##, ###, #### pb0.001 with respec
by Tukey's Test.DMEM with the supplements. Cells were maintained at 37 °C with
a medium change every 3 days. Four weeks later, cell aggregates
with diameters of 0.2 mm or larger (containing approximately 50
or more cells) were counted as colonies. The entire experiment
was performed twice.2.9. Real time PCR
Total mRNA was isolated from HEK293 cells by using the TRIZOL
protocol (Invitrogen). Reverse transcription was carried out by using
the SuperScript II kit (Invitrogen) per the manufacturer's instruc-
tions. For gene expression analysis, qPCR was performed by using
sequence-speciﬁc primers for: Vimentin forward 5'-GAACCTGAGG
GAAACTAATCTG-3′ and reverse 5′- CTGAGAAGTTTCGTTGA-TAACC-
3′, RAC3 forward 5′-AAGTGAAGAGGGATCTGGA-3′ and reverse 5′-
CAGATGACTACCATTTGAGG-3′ and GFP forward 5′-ACCATCTTCTTCAAer-expression.A. HEK293 cells were co-transfected with κB-Luc reporter plasmid plus
ls were stimulated for 30 min with 30 nM TSA or DMSO, prior to treatment with PMA
s an expression vector for CD1 (0.15 μg). Relative luminiscence units (RLU) are the
values. C. RAC3 mRNA expression normalized to the mRNA expression of GFP and
1 with respect to the same amount of CD1 expression vector but without TSA.# pb0.001
t to the same amount of RAC3 expression vector without CD1 expression vector.Analyzed
1124 M.F. Rubio et al. / Biochimica et Biophysica Acta 1823 (2012) 1119–1131GGACGA-3′ and 5′-GGCTGTTGTAGTTGTACTCC-3′. For all analyses,
GADPH forward 5′-TCTCCTCTGACTTCAACAGC-3′ and reverse 5′-
GTTGTCATACCAGGAAATGA-3′ was used as an internal control.3. Results
3.1. Cyclin D1 plays an inhibitory role over NF-κB transcriptional activity
Since NF-κB activity is affected by some of the molecules that
bind to CD1, we therefore hypothesized that this cyclin might affect
the transcriptional activity of NF-κB. In order to verify this, HEK293
cells were co-transfected with a κB-Luc reporter plasmid in the pres-
ence or absence of different mass (0.1, 0.15 and 0.2 μg) of a vector
encoding for CD1 or an empty vector, and the control β-Gal plasmid.
Transfected cells were stimulated with 10 ng/ml of PMA and Luciferase
activity was measured after 6 h. We found that increased levels of CD1
expression vector inhibited NF-κB activity (Fig. 1A ~40% inhibition,
bars 2 vs 4). The levels of CD1 after transfection with the CD1 ex-
pression vector are shown in Fig. 1B.
In order to determine if this inhibitory effect is mediated by a spe-
ciﬁc action of CD1, we performed additional experiments of κB-Luc
reporter assays where the HEK293 cells were also transfected with
an expression vector for the siRNA of CD1 that clearly inhibits CD1 ex-
pression (Fig. 1C). As shown in Fig. 1D, the inhibition of endogenous
CD1 signiﬁcantly increases the NF-κB transactivation in basal orFig. 4. Cyclin D1 is part of a protein complex that binds to NF-κB binding sites in the chroma
180 min, and chromatin cell lysates were prepared. ChIP assays performed by immunoprecip
by transfection of HEK293 cells with the expression vector for CD1 siRNA (0.2 μg), and nucl
(0.2 μg). The bands observed correspond to the fragment of CD1 promotor containing the κB
antibody (data not shown). C. The diagram bars correspond to the average of RLU±SD of t
promCD1-Luc plus CD1 expression vector or the empty control, in the presence or not of th
was determined after 24 h. D. ChIP assay as in A, but corresponding to the IκB-α promoter.*
to the values without CD1 over-expression plus PMA.stimulated conditions and blocks the inhibitory effect of the CD1 ex-
pression vector.
A similar CD1 effect was observed when NF-κB was activated using
20 ng/ml of TNF-α, an inﬂammatory cytokine that exerts several phys-
iological actions and is a powerful inducer of the canonical NF-κB
pathway [32,33]. Fig. 1E shows an inhibition of 45% for 0.1 μg of CD1
expression vector respect to the empty vector transfected cells.
In order to determine the effect of CD1 over an endogenous NF-κB
target gene, we analyzed if the expression of Vimentin is modiﬁed by
changes in the levels of CD1. HEK293 cells were transfected with dif-
ferent mass of CD1 expression vector and then stimulated with PMA
during 18 h. The levels of Vimentin and its mRNA were analyzed by
Western blot and Real time PCR. Fig. 1F and G shows that the increase
of CD1 inhibits the expression of Vimentin in agreement with the
results obtained on κB-Luc reporter assays.
3.2. Cyclin D1 does not inhibit the NF-κB nuclear translocation
NF-κB dimmers are sequestered in the cytoplasm as latent com-
plexes through binding to members of a family IκB proteins [1]. Be-
cause CD1 has an inhibitory effect on NF-κB transcriptional activity
when activation is induced by both PMA and TNF-α, it shows to be in-
dependent of the activation pathway. Thus, we ﬁrst hypothesized that
CD1 might inhibit the nuclear translocation of NF-κB or the DNA-
binding ability of the transcription factor. Afterwards, the levels of
nuclear active NF-κB were analyzed by EMSA. In these experiments,tin.A. HEK293 or B. T47D cells were stimulated with TNF-α (20 ng/ml) for 15, 30, 60 or
itation with Rel-A, CD1, RAC3 or HDAC1 antibody. Nuclear levels of CD1 were inhibited
ear localization of Rel-A was inhibited by transfection with the ssIkB expression vector
elements ampliﬁed by PCR. No bands were detected in the presence of the non-related
riplicates and relative to RSV-β gal activity. HEK293 cells transfected with the plasmid
e ssIκB expression vector were stimulated with 10 ng/ml of PMA and reporter activity
pb0.001 with respect to the values in unstimulated conditions.** pb0.001 with respect
Fig. 4 (continued).
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empty vector and NF-κB activation was induced by PMA stimulation.
As shown in Fig. 2A, the increased levels of CD1 did not inhibit the
amount of active NF-κB available in the nucleus that could bind the
speciﬁc oligonucleotide (Fig. 2A), indicating that CD1 does not antag-
onize with NF-κB activation.
The composition of these complexes was conﬁrmed by perform-
ing super-shift experiments in the presence of antibodies against
p50 or Rel-A subunit of NF-κB (Fig. 2B compare lanes 2 3, and 4). In
addition, the speciﬁcity of binding was determined by competition
assays using the speciﬁc unlabeled κB oligonucleotide (Fig. 2B com-
pare lanes 2 5, 6,and 7). The composition of the complexes is indicat-
ed in the ﬁgure.
The absence of CD1 inhibition of NF-κB nuclear translocation
after 3 h of PMA stimulationwas also conﬁrmed byWestern blot exper-
iments, performed with the nuclear proteins from each experimental
condition (Fig. 2C). Thus, these results demonstrate that CD1 does not
inhibit NF-κB nuclear translocation or its ability to bind DNA.Moreover,the effect of CD1 over NF-κB activity involves a mechanism that is sub-
sequent to nuclear translocation and DNA binding.
3.3. The repression of NF-κB transactivation by CD1 involves a
deacetylase activity
It has been previously demonstrated that CD1 inhibits the ac-
tivity of TR and AR, through HDAC recruitment [28,29]. In order
to investigate whether the CD1-mediated repression of NF-κB involves
a deacetylase activity, we analyzed the effect of 30 nM TSA over the
κB-Luciferase activity in presence of different levels of CD1. As
shown in Fig. 3A, the transactivation of NF-κB, induced by PMA,
increased 22-fold with respect to the basal conditions, while this
activation was inhibited by CD1 over-expression (~40% inhibition;
bar 4 with respect to bar 2). However, treatment with TSA inhibits
the repressive action of CD1 in cells transfected with low levels of
this expression vector (bar 12 with respect to bar 4), indicating
that deacetylases are involved in the CD1 transrepression of NF-κB.
Although the absence of a more signiﬁcant effect of TSA under
high levels of CD1 could be suggesting additional CD1 repressive
mechanisms, our results are in agreement with previous observa-
tions concerning the HDAC recruitment by CD1 and demonstrate
that these molecules are involved in CD1 inhibition of NF-κB.
3.4. The NF-κB activity is regulated by the levels of CD1 and RAC3 in an
antagonistic way
RAC3 is a NF-κB coactivator that has and recruits HAT activity
[6,34]. In view of our results, concerning the participation of HDACs
in the CD1 mediated transrepression of NF-κB, we hypothesized
that increased levels of RAC3 could revert the effect of CD1 by increas-
ing the NF-κB activity.
Therefore, we performed κB-Luc reporter assays in order to analyze
the activity of NF-κB, in HEK293 cells co-transfected with increasing
mass of the RAC3 expression vector, with or without a constant mass
of CD1 expression vector. Fig. 3B shows that high levels of RAC3, as
expected, increase the activity of NF-κB, while high levels of CD1 inhibit
the NF-κB coactivator role of RAC3. Interestingly, under the highest
mass of RAC3 together with high CD1 expression (bar 12) the values
are similar to that obtained in the absence of both expression vectors
(bar 2).
These studies indicate that RAC3 and CD1 antagonize in their func-
tion over the NF-κB activity, which is sensitive to the relative amounts
of these proteins.
3.5. Cyclin D1 regulates transcriptional activity of NF-κB as part of a
protein complex that binds to DNA at NF-κB binding sites
The abundance of CD1 affects local histone acetylation and methyla-
tion of speciﬁc promoters, as detected in chromatin immunoprecipitation
assays [35]. Therefore, it is possible that CD1 could be regulating the
NF-κB activity by altering local chromatin structure, through the re-
cruitment of corepressors over the promoters of target genes.
Since CD1 expression inhibits the activity of NF-κB, and this was
partially reversed by deacetylase inhibitor or over-expression of RAC3,
we decided to investigate if CD1 and NF-κB may be co-associated in
the context of the local chromatin structure of an NF-κB target gene.
We used a chromatin immunoprecipitation assay to analyze the
binding of Rel-A, RAC3, HDAC1 and CD1 to a DNA fragment of CD1
promoter containing κB binding elements [14]. These experiments
were performed in HEK293 and T47D cells and NF-κB was activated
by TNF-α treatment (Fig. 4A and B respectively). The recruitment of
these molecules was monitored during a time frame of 15–180 min
after stimulation.
Fig. 4A and B shows that Rel-A/DNA interaction is increased at
30 or 15 min respectively and reduced at 60 minutes post TNF-α
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association with its own promoter even in the absence of TNF-α
treatment; however, its recruitment was increased after stimula-
tion, peaked at 15 min and gradually reduced after 30 min. This
result suggests that CD1 can be a player in the regulation of NF-κB trans-
activation, perhaps acting like a corepressor assisting in the recruitment
of HDAC.
RAC3 was examined in the same experimental conditions. In-
terestingly, when we compared the patterns of RAC3/DNA associ-
ation between HEK293 cells and T47D cells (Fig. 4A versus B), we
observed that the kinetic of DNA association was different. While
in HEK293 cell line RAC3 association was increased at 15 min and re-
duced after 30 min of stimulation, in T47D theRAC3 recruitment peaked
at 15 min and remained associated after 180 min of TNF-α stimulation.
Concerning HDAC1 recruitment to CD1 promoter, we could observe
in both cell lines a particular kinetics: it was associated to DNA in the
absence of treatment similar to that observed for CD1 and reduced
after 30 min of TNF-α stimulation, just when Rel-A/DNA association
peaked. Moreover, while in HEK293 cell line HDAC binding was in-
creased again at 60 min, in T47D cells re-association occurs after
180 min of stimulation.
These results demonstrate that CD1 exerts an inhibitory effect
over NF-κB, acting at the promoter level, where the transcription
factor bounds and follows a kinetic association that is synchronized to
the recruitment of other coregulators that regulate the on/off for the
NF-κB target gene.
In order to determinate whether HDAC1 association to the NF-κB
target promoter depends on the CD1 recruitment, a similar experi-
mental model was performed in HEK293 cells, but using the CD1
siRNA expression vector. Fig. 4A shows that inhibition of the endog-
enous CD1 correlates with a lower recruitment of HDAC1 to the pro-
moter. Similar results were obtained for RAC3 recruitment under
conditions of Rel-A inhibition (Fig. 4A, right panel).
Because CD1 is a NF-κB target gene, we also analyzed the effect
of CD1 over-expression over its own promoter as a functional cor-
relate of these associations and its corepressor action. HEK293 cells
were co-transfected with a PromCD1-Luc reporter plasmid, the ex-
pression vector for CD1, or the empty control in the presence or
the absence of the NF-κB inhibitor ssIκB expression vector. The re-
porter activity was determined after PMA stimulation. Fig. 4C shows
that high levels of CD1 expression inhibit the NF-κB-induced transcrip-
tion from the CD1 promoter.
In order to determine if recruitment of CD1 to an NF-κB target
promoter is speciﬁc for the CD1 promoter, we performed ChIP as-
says analyzing a known target for NF-κB: the IκB promoter [31]. As
shown in Fig. 4D, CD1 is also recruited to this promoter.
3.6. Cyclin D1 and the transcription factor NF-κB could be part of the
same protein complex
In agreement with the obtained results, CD1 could be inhibit-
ing NF-κB transactivation at level of their target DNA sequence, sug-
gesting that at least for a short time after NF-κB stimulation, both
proteins could be part of the same protein complex. Therefore, we in-
vestigated if CD1 could be found associated to NF-κB proteins. In these
experiments T47D human breast tumor cells were stimulated with
PMA in order to activate NF-κB, and physical interaction was analyzed
by co-immunoprecipitation.
Fig. 5A shows that Rel-A was detected in the CD1 immunoprecip-
itate, while CD1 was detected in the Rel-A immunoprecipitate, indi-
cating that this member of the NF-κB family and CD1 could be part
of the same protein complex.
Since T47D cell line over-expresses CD1, at similar levels to
those reported previously for human breast cancer [36], we decid-
ed to analyze these interactions using an additional cell line with
normal levels of CD1, like the human embryonic kidney HEK293cells. As shown in Fig. 5B, results were similar to that observed in
T47D cells.
In addition, we also analyzed if Cdk4, the kinase partner of CD1,
could be part of this complex. Fig. 5A and B, shows, as expected, that
CD1 interacts with Cdk4, however this kinase is not part of Rel-A con-
taining complexes.
These results indicate that NF-κB and CD1 could be part of the
same protein complex, not depending on CD1 over-expression, and
independent of Cdk4 binding.
3.7. CD1 and RAC3 showed different cell cycle expression pattern and
their co-expression at high levels inhibits proliferation and anchorage-
independent growth
In order to determine the CD1 and RAC3 expression proﬁle,
HEK293 and T47D cell lines were synchronized for 16 hours serum
starvation.
As shown in Fig. 6A and B, both cell lines show a similar temporar-
ily gap between the CD1 and RAC3 expression proﬁles. While CD1
peaked 3 h after serum addition, RAC3 expression was increased 3 h
later in both cell lines. These results suggest that the expression of
both proteins is synchronized following particular kinetics, perhaps
in agreement with their role in the cell cycle.
Since NF-κB is regulated by CD1 and RAC3, with antagonic effects,
we also analyzed the basal NF-κB activity in HEK293 cells, by reporter
assays, at the same time that CD1 and RAC3 expression levels were
measured. As shown in Fig. 6C, maximum activity of NF-κB coincides
with minimal CD1 expression levels, showing a proﬁle that is in
agreement with the expected CD1 and RAC3 roles on NF-κB activity.
In order to analyze if CD1 and/or RAC3 over-expression may affect
the cell proliferation, HEK293 cells were transfected with expression
vectors for CD1, RAC3 or both together, and then cells were synchro-
nized for 16 h by serum starvation. Cell proliferation was evaluated
after 0, 12 and 24 h of serum addition, by staining with crystal violet.
As expected, CD1 over-expression induced proliferation (Figure. 6D).
The same results were obtained when RAC3 was over-expressed.
Moreover, high levels of RAC3 could bypass the absence of growth
factors promoting cell proliferation. However, the results obtained
when both RAC3 and CD1 were simultaneously over-expressed, were
particularly surprising because we observed a marked inhibition of
cell proliferation, indicating there is an antagonism over the prolifera-
tive signaling induced by each one of these molecules when both are
co-expressed at high levels and at the same time.
It has been previously demonstrated that RAC3 has a transform-
ing role [37]; therefore, we also analyzed its transforming role and
the effect of CD1 over-expression in the non tumoral HEK293 cells,
that are naturally unable to growth in soft agar. As shown in Fig. 6E,
cells transfected with an expression vector for the coactivator acquire
the ability to form colonies in soft agar, similar to that observed in the
tumoral T47D cell line. However, HEK293 with a simultaneous and
constitutive RAC3 and CD1 over-expression are unable to form col-
onies, showing a phenotype similar to non tumoral cells (Fig. 6E).
4. Discussion
Aberrant RAC3 and CD1 expression [38,39] has been linked to
multiple types of human cancer and tumoral progression, and both
proteins have an important role in the control of cell proliferation
[40–42]. The present work describes a new role for Cyclin D1 as a
NF-κB corepressor.
It is well documented that CD1 has several effects that are inde-
pendent to its role in the cell cycle, acting as a coactivator or core-
pressor [26–29]. This cyclin strongly inhibits ligand-dependent AR
activation [27] and it has been recently suggested that may compete
with p/CAF coactivator for AR binding, and that the excess of coacti-
vator expression may abrogate the repressor function of CD1 [28]. In
Fig. 5. Cyclin D1 and the transcription factor NF-κB are part of the same protein complex.Whole cells extracts from A. T47D or B. HEK293 cells stimulated with PMA (10 ng/ml) for
45 minutes, were immunoprecipitated (IP) with CD1, Rel-A or Cdk4 antibodies. The immunoprecipitates were analyzed by Western blot with the same antibodies. NS corresponds
to not immune serum immunoprecipitation.
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repression is partially reversed when a coactivator with intrinsic HAT
activity is over-expressed, and it depends on deacetylase activity.
In response to cellular cues there is a turnover in the nuclear or
cytoplasmatic localization of CD1 andNF-κB. Speciﬁcally, NF-κB translo-
cates to the nucleus after IκB phosphorylation followed by proteaso-
mal degradation [2]. Although it could be possible that CD1 inhibited
NF-κB activity through cytoplasmic sequestration or blocking the DNA-
binding activity of the transcription factor, we demonstrated that over-
expression of CD1 did not prevent NF-κB nuclear translocation or its
ability to bind DNA.
There are several studies showing transcriptional repression medi-
ated by CD1 and involving the recruitment of HDAC activity [28,29]. In
this work we examined the ability of the deacetylase inhibitor TSA
to relieve CD1-mediated repression, and we observed that this
inhibitor partially reversed the inhibitory action of CD1 over NF-κB.
These data indicate that deacetylation is involved in the CD1 corepres-
sor function probably through the recruitment of HDAC molecule to
the NF-κB complex. Alternatively, it is possible that CD1 action is
dependent on deacetylase activity but independent of histones. For
example, it has been shown that Rel-A subunit can be acetylated by
p300 [43], and Rel-A deacetylation by HDAC3 increases the interac-
tion with IκB-α and the cytoplasm localization of the complex [44].However, in our experiments no changes on nuclear Rel-A levels
were found under PMA stimulation and increased expression of
CD1, suggesting that this is not themechanism bywhich CD1 inhibits
NF-κB activity, at least under PMA treatment.
We found that the inhibition of endogenous CD1 by siRNA increases
NF-κB activity, in a similar way that the increase found under PMA
treatment. These results are in agreement with the inhibitory role for
CD1 over NF-κB activity, even under physiological levels of expression
for both molecules. Moreover, the ChIP assays demonstrate that CD1
could be part of a protein complex bound to κB elements that correlates
with increased HDAC1 recruitment. Afterwards, inhibition of endoge-
nous CD1 could be increasing the basal transcriptional activity of this
transcription factor.
Because the binding of coactivators to transcription factors in the
chromatin context is able to displace corepressor complex, we ana-
lyzed if RAC3 over-expression could reverse CD1-mediated repres-
sion. Our results shown, as expected, that increased levels of RAC3
enhanced NF-κB transactivation and partially reverted the CD1 trans-
repression. Moreover, there is an antagonistic effect between CD1 and
RAC3 over NF-κB transactivation that depends of the relative levels of
these proteins.
In ER-negative human breast cancer, constitutive NF-κB activity is
required for tumoral progression and cell proliferation [13,45]. We
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the same protein complex and this may induce CD1 expression [14].
The fact that CD1 expression and CD1/Cdk4 kinase activity are re-
quired for cell cycle progression [41], reveals a paradox on NF-κB-
dependent proliferation: while CD1 is a target gene for NF-κB [46],
it could also exert an anti-mitogenic function independent of Cdk4,
inhibiting NF-κB activity as a feedback mechanism.
It has been previously shown that during cell cycle progression,
the transition from G1 to S phase occurs with reduced levels of CD1Fig. 6. Expression of CD1 and RAC3 is differentially regulated during the cell cycle, and their c
T47D cells were synchronized by serum deprivation for 16 h and then released to the cell c
times after serum stimulation for Western blot analysis. Time curves correspond to the aver
pendent experiments. C. HEK293 cells were transfected with a reporter κB-Luc plasmid and
malized with the corresponding β-gal values. D, E and F. HEK293 cells transfected with C
determined by crystal violet staining after 0, 12 or 24 h of serum stimulation. E. and F. H
with soft agar, and plated for colony formation E. Four weeks later, colonies were counted
the average colonies±SD per ﬁeld (from no less than 10 ﬁelds).* pb0.001 with respect to th
at 0 time.# pb0.001 with respect to the κB-Luc activity at 0 time.a pb0.001 with respect to t
24 h; c and f pb0.001 with respect to the values obtained with RAC3 over-expression at 12 a
at 12 and 24 h.In all cases analyzed by Tukey's Test.[4,5]. Among other mechanisms, this diminish effect could be the re-
sult of CD1 repression over NF-κB activity. This is consistent with the
results of ChIP assays, where CD1 is able to bind κB-sequences, of its
own promoter, in unstimulated conditions and may also recruit
HDAC1. However, when NF-κB activity was stimulated, we observed
a displacement of corepressor complex and a recruitment of RAC3.
These observations suggest a model where the activation of NF-κB
induces CD1 expression and cell cycle progression, but under high
levels, CD1, could bind to its own promoter and recruit corepressoro-expression inhibits proliferation and anchorage-independent growth.A. HEK293 or B.
ycle by changing to medium containing 10% FBS. Cells were harvested at the indicated
age of relative densitometric units, with respect to the tubulin expression of ﬁve inde-
synchronized as in A. RLU corresponds to the average of triplicates±SD, and was nor-
D1, RAC3, CD1 plus RAC3, or with the control vector D. Viability of HEK293 cells was
EK293 cells harvested 24 h after transfection, resuspended as individual cells, mixed
and digital images of representative ﬁelds were captured. F. Bar diagram represents
e CD1 expression levels at 0 time.** pb0.001 with respect to the RAC3 expression levels
he empty vector at 0 time; b and e pb0.001 with respect to the empty vector at 12 and
nd 24 h; d and g pb0.001 with respect to the values obtained with CD1 over-expression
Fig. 6 (continued).
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should be probably dependent of co-regulator levels and additional
regulatory signals.
Herein, we demonstrated that the simultaneous CD1 and RAC3
over-expression has profound anti-proliferative effects, underscoring
the importance of relative CD1 and RAC3 levels on tumors.
RAC3 is linked to cancer because itwas found often ampliﬁed and/or
over-expressed in several tumors [38,47–49]. Previous works showed
no correlation between RAC3 and CD1 ampliﬁcation, suggesting that
these events may represent two different types of breast tumors [47].
Then, what happens to cells that over-express both of thesemolecules?
Our results suggest that despite the deregulation in the expression
levels, the cells still retain its cell cycle-dependent regulation.
RAC3 expression is required for both normal and malignant cells
to effectively enter to S phase [42]. Moreover, our results indicate
that RAC3 expression appears to be cell cycle regulated both in tu-
moral and non-tumoral cells. Despite these studies, little is known
about how elevated levels of RAC3 and CD1 may induce tumorigene-
sis and/or promote tumor growth. Interestingly we observed that CD1
and RAC3 kinetics of expression was similar between both cell lines,
despite the differences concerning endogenous levels and tumoral
capabilities.
A recent work showed that the depletion of RAC3 does not affect
the expression of CD1, but its presence is necessary for the expression
of genes that are regulated by E2F1 [42].In agreement with these observations and our own results, it can
be suggested that in a physiological context, the antagonism observed
between RAC3 and CD1 on the NF-κB transactivation can be compen-
sated by a constitutive activation of NF-κB [50]. However, it is inter-
esting to remark that in our experiments of over-expression, both
molecules are under control of constitutive promoters, which are
not the natural targets for cell cycle control. Therefore, the normal ki-
netic of RAC3 and CD1 expression, shown in Fig. 6A and B, was abro-
gated. Therefore, our results suggest that this kinetic could be a key
element in avoiding cell cycle inhibition.
In summary, in this work, we demonstrated for the ﬁrst time that
CD1 can inhibit NF-κB activation; and is also a corepressor of this
transcription factor, that could be recruited to an NF-κB target pro-
moter and antagonize the RAC3 coactivator function (Fig. 7).
We conclude then that CD1 or RAC3 over-expression has a prolif-
erative and transforming role that contributes to tumor development.
However, a particular kinetic in the control of the relative expression
levels of both molecules is required for tumor promotion.Acknowledgements
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Fig. 7. Relative amounts of CD1 and RAC3 play a role in transforming and the balance of tumor cell proliferation.The levels of CD1 and RAC3 expression oscillate in the cell cycle.
Although high expression of each one of them is associated to tumor development and both have a role in the control of cell cycle, CD1 acts as a NF-κB corepressor while RAC3 is a
coactivator. Some NF-κB target genes that are involved in tumor development could be controlled in an opposite way by the recruitment of these molecules to their promoters.
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